Anavex Life Sciences Corp. (AVXL): Price and Financial Metrics


Anavex Life Sciences Corp. (AVXL): $9.71

0.65 (+7.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AVXL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AVXL Stock Price Chart Interactive Chart >

Price chart for AVXL

AVXL Price/Volume Stats

Current price $9.71 52-week high $31.50
Prev. close $9.06 52-week low $7.13
Day low $8.84 Volume 995,400
Day high $9.77 Avg. volume 1,072,890
50-day MA $10.36 Dividend yield N/A
200-day MA $15.01 Market Cap 751.64M

Anavex Life Sciences Corp. (AVXL) Company Bio


Anavex Life Sciences Corporation is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers. The company was founded in 2006 and is based in New York, New York.


AVXL Latest News Stream


Event/Time News Detail
Loading, please wait...

AVXL Latest Social Stream


Loading social stream, please wait...

View Full AVXL Social Stream

Latest AVXL News From Around the Web

Below are the latest news stories about Anavex Life Sciences Corp that investors may wish to consider to help them evaluate AVXL as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: Applied DNA Sciences (APDN), Glaukos (GKOS) and Anavex Life Sciences (AVXL)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Applied DNA Sciences (APDN – Research Report), Glaukos (GKOS – Research Report) and Anavex Life Sciences (AVXL – Research Report) with bullish sentiments. Applied DNA Sciences (APDN) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Applied DNA Sciences, with a price target of $6.00. The company's shares closed last Thursday at $3.11, equals to its 52-week low of $3.11. According to TipRanks.

Howard Kim on TipRanks | February 11, 2022

BTIG Thinks Anavex Life Sciences’ Stock is Going to Recover

In a report released yesterday, Yun Zhong from BTIG reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $35.00. The company's shares closed last Wednesday at $11.74, close to its 52-week low of $9.93. According to TipRanks.com, Zhong is ranked 0 out of 5 stars with an average return of -22.8% and a 16.2% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Sarepta Therapeutics, and Sio Gene Therapies. Currently, the analyst consensus on Anavex Life Sciences is a Strong Buy with an average price target of $31.50, which is a 180.2% upside from current levels.

Brian Anderson on TipRanks | February 10, 2022

Anavex Life Sciences (AVXL) Q1 2022 Earnings Call Transcript

AVXL earnings call for the period ending December 31, 2021.

The Motley Fool | February 10, 2022

Anavex Life Sciences Corp. (AVXL) Is A Possible Investment At Current Levels

Anavex Life Sciences Corp. (NASDAQ:AVXL) price on Wednesday, February 09, rose 5.77% above its previous days close as an upside momentum from buyers pushed the stocks value to $11.74. A look at the stocks price movement, the close in the last trading session was $11.10. The beta value (5-Year monthly) was 0.61. Turning to its Anavex Life Sciences Corp. (AVXL) Is A Possible Investment At Current Levels Read More »

Stocks Register | February 10, 2022

Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in the virtual 11 th Annual SVB Leerink Global Healthcare Conference and present on Wednesday, February 16 at 3 pm ET.

GlobeNewswire | February 10, 2022

Read More 'AVXL' Stories Here

AVXL Price Returns

1-mo 8.01%
3-mo -9.59%
6-mo -52.50%
1-year -22.01%
3-year 217.32%
5-year 65.14%
YTD -44.00%
2021 221.11%
2020 108.49%
2019 66.03%
2018 -51.55%
2017 -18.69%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4872 seconds.